The TGA has slapped a boxed warning on the gout drug febuxostat following concern over an increased risk of death in patients who have major cardiovascular disease.

This follows a US study last year of more than 6000 patients with gout and CVD, which found all-cause and cardiovascular mortality were higher among those taking febuxostat compared with the first-line urate-lowering medication allopurinol.